Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -8.85% | 20.70% | -17.30% | -4.43% | -1.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.85% | 20.70% | -17.30% | -4.43% | -1.22% |
| Cost of Revenue | 0.89% | 20.96% | -62.92% | -55.30% | -39.69% |
| Gross Profit | -11.40% | 20.65% | 9.46% | 20.91% | 18.59% |
| SG&A Expenses | 26.01% | -14.60% | 0.67% | -27.41% | -16.42% |
| Depreciation & Amortization | -91.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.30% | 37.22% | -17.73% | -29.02% | -17.65% |
| Operating Income | -6.53% | -69.58% | 19.27% | 73.84% | 36.39% |
| Income Before Tax | -44.63% | -1,286.01% | 20.06% | 43.61% | 22.26% |
| Income Tax Expenses | 105.59% | -1,666.98% | -174.51% | -107.40% | -889.92% |
| Earnings from Continuing Operations | -62.83% | -1,237.61% | 35.85% | 79.90% | 31.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.83% | -1,237.61% | 35.85% | 79.90% | 31.39% |
| EBIT | -6.53% | -69.58% | 19.27% | 73.84% | 36.39% |
| EBITDA | -168.69% | -27.14% | 111.01% | 140.24% | 58.53% |
| EPS Basic | -62.83% | -1,214.44% | 35.95% | 86.02% | 63.40% |
| Normalized Basic EPS | -5.45% | -633.00% | 11.12% | 63.55% | 60.99% |
| EPS Diluted | -62.85% | -2,105.20% | 35.91% | 86.02% | 63.40% |
| Normalized Diluted EPS | -5.45% | -1,216.75% | 11.12% | 63.55% | 60.99% |
| Average Basic Shares Outstanding | 0.00% | 2.08% | 0.16% | 43.75% | 87.44% |
| Average Diluted Shares Outstanding | 0.00% | -43.19% | 0.16% | 43.75% | 87.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
